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ous data collection methods; to provide an interactive fo-
rum for discussing recommendations for the use of each
method; and to discuss the implications that alternative
measurement strategies may have on reported results.
PARTICIPANTS WHO WOULD BENEFIT: This ses-
sion is directed at individuals who are responsible for the
design and conduct of pharmacoeconomic evaluations.
Individuals who need to interpret study results will also
benefit from this workshop.
Pharmacoeconomic studies are often designed without
the appropriate concern for, or justification of, the data
collection method used. Previous research has focused
mainly on what data to collect rather than how to col-
lect the data. This current research focuses on the issue
of study validity through the use of various data collec-
tion strategies. This workshop will discuss the appropri-
ate application of each strategy and provide recommen-
dations for the employment of particular data collection
methods in the context of specific studies. Methodolo-
gies to be discussed include office-based self-administra-
tion, patient diaries, face-to-face interviews (written and
oral), telephone interviews (personal and CATI), and
postal surveys. The research presented here augments
earlier research by informing researchers of potential is-
sues with data collection techniques on resource utiliza-
tion collection.
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WORKSHOP OBJECTIVE: Advances in treatment for
schizophrenia and the development of evidence-based
standards of care demand better methods for population-
based research on this disease and routine assessment of
treatment outcomes in systems of care. The purpose of
this workshop is to introduce the Schizophrenia Care and
Assessment Program Health Questionnaire (SCAPHQ),
a brief instrument to measure the clinical and functional
outcomes of care for schizophrenia. We will describe the
rationale for the instrument, the process of its develop-
ment, and its scope of measurement. We will discuss the
validity of the SCAPHQ in relation to concurrent ad-
ministration of major clinical and functional instruments for
schizophrenia. We will consider applications of SCAPHQ
in longitudinal studies and present results of its use in this
context. The participant will understand potential appli-
cations of the instrument in research and routine assess-
ment.
PARTICIPANTS WHO WOULD BENEFIT: Providers
of care for schizophrenia and researchers with interest in
methods to measure and monitor outcomes of treatment
in actual care settings.
Schizophrenia affects about one percent of the popula-
tion and exacts substantial human and economic costs.
We will discuss the development, validation, and applica-
tions of a new instrument (SCAPHQ) to assess out-
comes of care for this disease in research or routine clini-
cal assessment. We will address measurement of patients’
disease status (symptoms, side effects), generic health sta-
tus, functional status (productivity, social relations, daily
activities, leisure), quality of life, and safety and welfare.
We will evaluate the instrument’s performance with re-
spect to internal consistency, test-retest reliability, and
criterion validity in comparison to existing instruments.
We will discuss use of the instrument to model the effect
of prior period clinical status, medication therapy, and
other patient characteristics on clinical and functional
outcome. Participants with interest in patient-centered
methods for schizophrenia outcomes assessment will ben-
efit from this workshop.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to present Multiple Disease Risk Assessment
2000 (MDRA 2000), a tool for empiric assessment of
disease risk factors, categorization of patients at risk, and
monitoring of patient outcomes.
PARTICIPANTS WHO WOULD BENEFIT: Health-
care decision-makers and others involved in the process
of monitoring and evaluating patient outcomes.
Identifying patients at risk for disease and providing ap-
propriate care can improve patient outcomes and results
in significant cost reductions to healthcare systems. Mul-
tiple Disease Risk Assessment 2000 provides clinicians
with a valuable tool for performing a systematic analysis
of patients at risk of developing a selected disease, infec-
tion, or medical complication. The tool can identify pres-
ence of key risk factors, serve as a guideline for initiating
a therapeutic intervention, and can help identify factors
